Health Care·Health Care Equipment·$12.9B
Penumbra Inc is a healthcare company that develops innovative medical devices for neuro and peripheral vascular conditions. With a market cap of $13 billion, it plays a significant role in the health care equipment sector, focusing on improving patient outcomes through advanced technology.
Earnings Per Share (EPS)
EPS is a key indicator of profitability and performance, and investors will be looking for continued growth.
Revenue Growth
While specific revenue estimates are not available, any growth in revenue will signal strong demand for Penumbra's products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
7Q
EPS Beat Rate
88%
Avg EPS Surprise
+10.78%
Avg Stock Reaction
-0.89%
In Q4 2025, Penumbra reported an EPS of $1.18, exceeding expectations by 5.36%. However, the stock saw a slight decline the following day, indicating mixed investor sentiment.
Management Promises & Guidance
Overall expectations for Penumbra's upcoming earnings are cautious, given the lack of analyst estimates and mixed reactions to past earnings.
Bull Case
If Penumbra continues its trend of beating EPS estimates, it could signal strong operational performance and growth potential, attracting more investor interest.
Bear Case
Conversely, any signs of slowing growth or missed expectations could lead to further declines in stock price, as seen in recent quarters.
Earnings Per Share (EPS)
N/AEPS is a key indicator of profitability and performance, and investors will be looking for continued growth.
Revenue Growth
N/AWhile specific revenue estimates are not available, any growth in revenue will signal strong demand for Penumbra's products.
The print will turn on these two things.
Q1
What will the EPS be for Q1-2026?
Given the company's history of beating EPS estimates, this figure will be crucial in determining market sentiment and stock performance.
Q2
What insights can management provide on revenue growth?
Understanding revenue trends will help investors gauge demand for Penumbra's products and overall market position.
Why consensus could be wrong
The Street may underestimate Penumbra's ability to innovate and capture market share, especially given its recent strong EPS surprises.
Supporting Evidence
Penumbra has consistently beaten EPS estimates, indicating strong operational execution.
The company's focus on innovative medical devices positions it well against competitors.
Recent industry trends suggest increasing demand for advanced healthcare solutions.
Key Risk
If the EPS comes in above $1.25, it could challenge the current market skepticism and shift sentiment positively.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Penumbra can maintain its growth trajectory amidst increasing competition in the healthcare equipment sector.
Bull Confirmed If
An EPS of $1.25 or higher would confirm strong operational performance and growth potential.
Bear Confirmed If
An EPS below $1.00 could indicate slowing growth and lead to a negative market reaction.
Implied Move
±N/A
There is currently no options market data available to gauge investor sentiment leading up to the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Penumbra beats expectations with strong EPS and revenue growth, history suggests the stock could rise by an average of 1.46%, confirming a bullish outlook.
In-Line / Cautious
If results come in line with expectations but management's commentary is cautious, the stock may experience little movement as investors reassess future growth.
Miss
A miss on EPS could lead to a decline in stock price, with history suggesting an average drop of around 0.77%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NORFOLK SOUTHN CORP
Apr 24, 2026